BlossomHill Therapeutics (NASDAQ:BLSM) Upgraded by HC Wainwright to “Strong-Buy” Rating

HC Wainwright upgraded shares of BlossomHill Therapeutics (NASDAQ:BLSM) to a strong-buy rating in a report issued on Tuesday,Zacks reports.

Several other equities analysts also recently commented on the company. Lifesci Capital initiated coverage on BlossomHill Therapeutics in a research report on Tuesday. They issued an “outperform” rating and a $32.00 target price on the stock. Wall Street Zen upgraded BlossomHill Therapeutics to a “hold” rating in a research note on Saturday, August 15th. Guggenheim began coverage on BlossomHill Therapeutics in a report on Tuesday. They issued a “buy” rating and a $30.00 price objective on the stock. Leerink Partners initiated coverage on BlossomHill Therapeutics in a report on Tuesday. They issued an “outperform” rating and a $36.00 price objective on the stock. Finally, JPMorgan Chase & Co. began coverage on BlossomHill Therapeutics in a research report on Tuesday. They set an “overweight” rating and a $28.00 price objective on the stock. Three research analysts have rated the stock with a Strong Buy rating and two have assigned a Buy rating to the company. According to data from MarketBeat, BlossomHill Therapeutics currently has an average rating of “Strong Buy” and a consensus price target of $32.20.

BlossomHill Therapeutics Stock Up 3.8%

BLSM opened at $18.99 on Tuesday. BlossomHill Therapeutics has a 12-month low of $15.25 and a 12-month high of $20.61.

Insider Buying and Selling

In other news, Director Bihua Chen acquired 312,500 shares of the stock in a transaction dated Monday, August 10th. The stock was bought at an average price of $16.00 per share, with a total value of $5,000,000.00. Following the completion of the purchase, the director directly owned 3,614,034 shares of the company’s stock, valued at $57,824,544. This represents a 9.47% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Orbimed Advisors Llc purchased 625,000 shares of the company’s stock in a transaction dated Monday, August 10th. The shares were acquired at an average cost of $16.00 per share, with a total value of $10,000,000.00. Following the purchase, the director directly owned 2,714,279 shares of the company’s stock, valued at approximately $43,428,464. The trade was a 29.91% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders acquired a total of 1,573,900 shares of company stock worth $25,181,900 in the last quarter.

More BlossomHill Therapeutics News

Here are the key news stories impacting BlossomHill Therapeutics this week:

• Positive Sentiment: Leerink Partners, HC Wainwright, and Guggenheim each upgraded BlossomHill Therapeutics to “strong-buy,” strengthening the analyst consensus around the company. Zacks analyst upgrade coverage
• Positive Sentiment: Lifesci Capital initiated coverage with an “outperform” rating and a $32 price target, implying substantial upside from the current level. Benzinga coverage initiation
• Positive Sentiment: JPMorgan initiated coverage with an “overweight” rating and a $28 price target, adding another major-bank endorsement and signaling confidence in BlossomHill’s growth prospects. Tickerreport JPMorgan coverage
• Positive Sentiment: BlossomHill will present updated Phase 1/2 SOLARA trial data for BH-30643 at the 2026 World Conference on Lung Cancer. The presentation will cover anti-tumor activity in EGFR-mutant non-small-cell lung cancer patients with resistance mutations such as C797S. BH-30643’s FDA Fast Track designation and its potential to address an area without approved oral targeted therapies provide important pipeline catalysts. BlossomHill SOLARA trial data announcement
• Positive Sentiment: A report highlighted insider buying of BlossomHill shares, which may be viewed as a signal of management confidence ahead of upcoming clinical and corporate catalysts. Insider buying report

About BlossomHill Therapeutics

BlossomHill Therapeutics Inc is a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop small molecule medicines which address significant unmet medical needs in cancer treatment. The company’s lead clinical programs include BH-30643. BlossomHill Therapeutics Inc is headquartered in San Diego, California.